• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Executive Officer Castagna Michael was granted 27,000 shares, increasing direct ownership by 1% to 2,639,048 units (SEC Form 4)

    5/16/25 6:20:59 PM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MNKD alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Castagna Michael

    (Last) (First) (Middle)
    1 CASPER STREET

    (Street)
    DANBURY CT 06810

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    MANNKIND CORP [ MNKD ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Executive Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    05/14/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock, $0.01 Par Value 05/14/2025 A(1) 27,000 A $4.56 2,639,048 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The securities were purchased through the Issuer's Market Price Stock Purchase Plan effective May 13, 2023. The purchase was approved by the Company's Board of Directors on May 14, 2025.
    /s/ Michael Castagna 05/16/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $MNKD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MNKD

    DatePrice TargetRatingAnalyst
    4/10/2025$12.00Outperform
    Mizuho
    2/10/2025$11.00Outperform
    Wedbush
    12/20/2024$9.00Overweight
    Wells Fargo
    12/19/2024$7.00 → $10.00Sector Perform → Outperform
    RBC Capital Mkts
    9/9/2024$7.00 → $8.00Outperform
    Leerink Partners
    6/13/2024$8.00Buy
    Rodman & Renshaw
    10/10/2023$10.00Outperform
    Wedbush
    2/28/2022$6.50 → $6.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $MNKD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mizuho initiated coverage on Mannkind with a new price target

      Mizuho initiated coverage of Mannkind with a rating of Outperform and set a new price target of $12.00

      4/10/25 12:42:30 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Mannkind with a new price target

      Wedbush initiated coverage of Mannkind with a rating of Outperform and set a new price target of $11.00

      2/10/25 7:01:41 AM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Mannkind with a new price target

      Wells Fargo initiated coverage of Mannkind with a rating of Overweight and set a new price target of $9.00

      12/20/24 7:44:06 AM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNKD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association's 85th Scientific Sessions in Chicago, June 20-23

      DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products and delivery devices for patients with endocrine and orphan lung diseases, will showcase inhaled insulin at the American Diabetes Association's (ADA) 85th Scientific Sessions from June 20-23 in Chicago. Dr. Michael J. Haller, Professor and Chief of Pediatric Endocrinology at the University of Florida, will present the results from the randomized period of the INHALE-1 clinical trial during a "Future Ready" symposium. Dr. Haller is the Chair for MannKind's Phase 3 INHALE-1 study of A

      6/9/25 4:05:00 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • INDYCAR Driver Conor Daly To Share His Personal Diabetes Story and Race Go-Karts With Detroit Area Youth On Thursday, May 29

      WESTLAKE VILLAGE, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will team up with NTT INDYCAR SERIES driver Conor Daly, who is living with Type 1 diabetes (T1D) for a one-of-a-kind experience with Detroit area youth and families during the week of the Chevrolet Detroit Grand Prix in downtown Detroit. Daly will share his personal story of being diagnosed with diabetes as a teen and how he does not let it keep him from living life without limits. The former karting champion will also provide some karting tips and then race go-karts to identify the Fastest 6. Daly was first diagnosed with diabetes at the age of 14, and today is the only known U.S. professional r

      5/27/25 9:15:00 AM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MannKind to Present at Upcoming Investor Conferences

      DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced its participation at the upcoming investor conferences. MannKind's Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss will share updates during the following investor conferences, both being held in New York City: RBC Capital Markets 2025 Global Annual Healthcare Conference Tuesday, May 20, 8:00 a.m. ET Jefferies Global Healthcare Conference Thursday, June 5,

      5/13/25 4:05:00 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNKD
    SEC Filings

    See more
    • MannKind Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - MANNKIND CORP (0000899460) (Filer)

      5/19/25 5:02:22 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by MannKind Corporation

      8-K - MANNKIND CORP (0000899460) (Filer)

      5/15/25 4:08:08 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by MannKind Corporation

      144 - MANNKIND CORP (0000899460) (Subject)

      5/13/25 4:02:55 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNKD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Pres, Endocrine Business Unit Marasco Dominic

      4 - MANNKIND CORP (0000899460) (Issuer)

      6/25/25 9:00:08 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Binder Steven B. sold $256,340 worth of shares (64,085 units at $4.00), decreasing direct ownership by 6% to 925,258 units (SEC Form 4)

      4 - MANNKIND CORP (0000899460) (Issuer)

      6/10/25 8:07:37 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP Chief Medical Officer Blank Burkhard covered exercise/tax liability with 15,630 shares, decreasing direct ownership by 3% to 465,124 units (SEC Form 4)

      4 - MANNKIND CORP (0000899460) (Issuer)

      5/27/25 7:26:54 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care